CervoMed Inc. Reports Material Agreements and Officer Changes

Ticker: CRVO · Form: 8-K · Filed: Apr 18, 2025 · CIK: 1053691

Cervomed Inc. 8-K Filing Summary
FieldDetail
CompanyCervomed Inc. (CRVO)
Form Type8-K
Filed DateApr 18, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, officer-changes, director-changes, filing

TL;DR

CervoMed filed an 8-K detailing new deals, terminated agreements, and exec changes. Keep an eye on this.

AI Summary

CervoMed Inc. filed an 8-K on April 18, 2025, reporting on several key events that occurred on April 14, 2025. These include entering into a material definitive agreement, terminating a material definitive agreement, and changes related to directors and officers, including compensatory arrangements. The filing also includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate actions, including new agreements and potential changes in leadership or compensation, which could impact the company's strategic direction and financial health.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and changes in officers, which can introduce uncertainty and potential shifts in company strategy.

Key Numbers

  • 20250414 — Event Date (Date of earliest event reported in the 8-K)
  • 20250418 — Filing Date (Date the 8-K was officially filed with the SEC)

Key Players & Entities

  • CervoMed Inc. (company) — Registrant
  • 001-37942 (company) — SEC File Number
  • 30-0645032 (company) — EIN
  • 20250414 (date) — Earliest event reported
  • 20250418 (date) — Filing Date

FAQ

What was the nature of the material definitive agreement entered into by CervoMed Inc. on April 14, 2025?

The filing indicates the entry into a material definitive agreement, but the specific details are not provided in the excerpt. Further review of the attached documents would be necessary.

What led to the termination of a material definitive agreement by CervoMed Inc. on April 14, 2025?

The filing states that a material definitive agreement was terminated, but the reasons for termination are not detailed in this summary. The full filing would contain more information.

Were there any changes in CervoMed Inc.'s directors or officers on or around April 14, 2025?

Yes, the filing reports on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements for certain officers, all related to events on or around April 14, 2025.

What is the SIC code for CervoMed Inc. and what industry does it represent?

The SIC code for CervoMed Inc. is 2834, which corresponds to Pharmaceutical Preparations.

What were CervoMed Inc.'s former company names?

CervoMed Inc. was formerly known as Diffusion Pharmaceuticals Inc. (name change effective 20160115), RestorGenex Corp (name change effective 20140307), and Stratus Media Group, Inc (name change effective 20080722).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 18, 2025 regarding CervoMed Inc. (CRVO).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.